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Context:  Antipsychotic  treatment  is the  ﬁrst-line  treatment  option  for  schizophrenia.  Individual  studies
suggested  they  can signiﬁcantly  affect brain  structure  and  account  for progressive  brain  changes  observed
during the  illness.
Objectives: To  quantitatively  examine  the effect  of  antipsychotics  as compared  to illness  related  factors
on progressive  brain  changes  in  schizophrenia.
Data  sources:  Electronic  databases  were  searched  until  April  2012.  All  magnetic  resonance  imaging  studies
reporting  progressive  brain changes  in  schizophrenia  subjects  and  antipsychotic  exposure  were  retrieved.
Study selection:  30 longitudinal  MRI studies  with  antipsychotic  administration  in  schizophrenia  patients
met  the  inclusion  criteria.
Data  extraction:  Brain  volumes  before  and  after  antipsychotic  exposure,  duration  of  illness,  severity  of
psychotic  symptoms  as  well  as  demographic,  clinical,  and  methodological  variables  were  extracted  from
each  publication,  or obtained  directly  from  its  authors.
Data synthesis:  The  overall  sample  was  of 1046  schizophrenia  patients  and  780  controls  for  a median  dura-
tion  of follow-up  of  72.4  weeks.  At baseline,  patients  showed  signiﬁcant  whole  brain  volume  reductions
and  enlarged  lateral  ventricle  (LV)  volumes  compared  to  controls.  No  baseline  volumetric  abnormalities
were  detected  in  the gray  matter  volumes  (GMV),  white  matter  volumes,  cerebrospinal  ﬂuid  and  caudate
nucleus.  Longitudinally,  there  were progressive  GMV  decreases  and  LV  enlargements  in patients  but  not
in controls.  The  GMV  decreases  were  inversely  correlated  with  cumulative  exposure  to  antipsychotic
treatments,  while  no effects  were observed  for  duration  of  illness  or  illness  severity.
Conclusions:  Schizophrenia  is characterized  by progressive  gray  matter  volume  decreases  and  lateral
ventricular  volume  increases.  Some  of these  neuroanatomical  alterations  may  be associated  with  antipsy-
chotic  treatment.©  2013  The  Authors.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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. Introduction
Antipsychotic medication is the mainstay of effective man-
gement of schizophrenia. The ﬁrst-generation ‘conventional’
ntipsychotic drugs are predominantly antagonists of dopamine
2 receptors, and are effective against most positive symptoms,
ut have high rates of extrapyramidal side effects (Miyamoto
t al., 2005). The second-generation or ‘atypical’ antipsychotics
iffer from previous antipsychotic agents in their lower afﬁnity
or dopamine- and other neuro-receptors (5-HT2A, adrenergic,
cetylcholine, and histamine receptors) (Leucht et al., 2009,
endall, 2011) with a reduced proﬁle of extrapyramidal side-effects
Miyamoto et al., 2005) but with comparable rates of adverse events
uch as sedation and weight gain (Leucht et al., 2009). Despite
hese pharmacodynamic differences, all antipsychotics cross the
rain–blood barrier to target receptors distributed in the brain,
ith a clinical efﬁcacy starting in the ﬁrst days of treatment and
ccumulating over time (Agid et al., 2003a). The effect of antipsy-
hotics on brain function starts immediately and can be detected
fter a single dose using molecular imaging techniques (Handley
t al., 2012). There is recent evidence indicating rapid structural
emodeling and short-term neural plasticity with acute D2 receptor
lockade (Tost et al., 2010). The reversibility of these ﬁndings and
heir clinical meaning, in particular in relation to the long-term out-
omes of schizophrenia are unknown (Schaufelberger et al., 2011).
owever, they provide converging evidence that antipsychotic
reatment, even acutely, can signiﬁcantly impact brain structure
nd function. This can be particularly relevant to the longitudi-
al course of the illness and partially account for the observed
ynamic brain changes associated with the disorder (Ho et al.,
011). A number of longitudinal structural Magnetic Resonance
maging (MRI) studies have found progressive brain changes in
dults with schizophrenia during the initial years after the onset of
he illness (Hulshoff Pol and Kahn, 2008, Kempton et al., 2010). The
xtent of progressive brain tissue decrease in patients (−0.5% per
ear) has been estimated as twice that of healthy controls (−0.2%
er year) (Hulshoff Pol and Kahn, 2008). These progressive brain
hanges have been associated with poorer clinical outcomes (Ho
t al., 2003; Cahn et al., 2006; van Haren et al., 2008), more nega-
ive symptoms, and a decline in neuropsychological performance,
lthough not consistently (van Haren et al., 2003). Currently, it is
ot clear when these structural brain changes occur and how they
evelop over time. However, studying individuals at clinical high
isk of developing psychosis (Fusar-Poli et al., 2012a) has allowed
he investigation of structural brain alterations before the onset of
he illness. MRI  studies addressing structural alterations in individ-
als at enhanced risk for psychosis have been recently summarized,
onﬁrming that some abnormalities are already present during the
rodromal phase (Fusar-Poli et al., 2011) and may  be predictive
f later transition to psychosis (Smieskova et al., 2010). Despite
vidence suggesting early brain changes in psychosis, the speciﬁc
ole played by antipsychotic treatment is strongly debated. Some
tudies have indicated that higher cumulative dose of antipsychotic .  . .  .  . .  . . .  . . . . .  . . .  .  . . .  .  . . . . . . .  . . . . . . .  .  . .  . . .  . . . . .  . . . .  .  . . . . .  .  .  .  .  . .  .  . . .  . . .  . 1690
medication intake is not associated with brain volume changes, and
may even be associated with less prominent volumetric changes
(Hulshoff Pol and Kahn, 2008). Conversely, recent investigations
in ﬁrst-episode patients showed increased antipsychotic exposure
was associated with brain volume reduction (Ho et al., 2011); and
that this association was stronger than illness-related effects. In
addition studies from other groups have indicated a differential
protective effect of atypical vs. typical antipsychotic on brain vol-
ume  changes in schizophrenia (Miyamoto et al., 2005).
Besides the potential effect of antipsychotics on brain structure,
other factors should be considered when discussing progressive
brain changes in schizophrenia. Two commonly investigated clini-
cal variables in the imaging literature are duration of illness (DOI)
and severity of illness.A plethora of imaging data are now avail-
able at different stages of the illness (Olabi et al., 2011) and a
recent voxel-based meta-analysis has directly tested the hypothe-
sis that patients with chronic schizophrenia have more extensive
brain abnormalities observed in the same regions as non-psychotic
relatives, subjects at high risk for psychosis and ﬁrst-episode sam-
ples (Chan et al., 2009). Subtraction analyses between these groups
conﬁrmed that gray matter abnormalities observed in the pro-
dromal phases of schizophrenia become more extensive through
ﬁrst-episode and chronic illness, conﬁrming the signiﬁcant role
played by illness duration on imaging results (Chan et al., 2009).
Severity of signs and symptoms is also associated with differ-
ent brain alterations in schizophrenia. For example MRI studies
conducted in antipsychotic-naïve subjects reported negative cor-
relations between positive psychotic symptoms and volumes of
temporal areas, and between negative symptoms and volume of
fronto-cerebellar areas (Venkatasubramanian, 2010). In particular
the association between gray matter reductions in the temporal
areas and severity of auditory hallucinations has been conﬁrmed
in several MRI  studies as well as in extensive voxel-based meta-
analyses (Modinos et al., 2012).
Given the above three confounders, the available qualitative
reviews addressing progressive brain changes in schizophrenia
have yielded inconclusive results (Vita and De Peri, 2007; Navari
and Dazzan, 2009; Smieskova et al., 2009; Moncrieff and Leo, 2010).
There are no studies investigating the consistency and magnitude
of progressive volumetric changes in schizophrenia in a quanti-
tative meta-analysis, controlling at the same time for the above
confounders. In the present study we  ﬁrst sought to examine at
a meta-analytical level whether schizophrenia is characterized by
progressive brain changes as compared to healthy controls. We
then aimed to investigate the effect of potential moderators affect-
ing brain structure such as illness duration, illness severity, and
antipsychotic treatment.2. Methods
The details of the research protocol are appended in the supple-
mentary protocol (S1).
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.1. Selection procedures
.1.1. Search strategies
A systematic search strategy was used to identify relevant
tudies. Three independent researchers (RS, PFP, SB) conducted a
hree-step literature search. First, a PubMed and Embase search
as performed to identify putative longitudinal MRI studies in
chizophrenia. The search was conducted up to end of April
012, with no time span speciﬁed for date of publication. The
ollowing search terms were used: “MRI” OR “neuroimaging”
ND “schizophrenia” AND “antipsychotic” AND “longitudinal” NOT
review”. In a second step the reference lists of the articles included
n the review were manually checked for any studies not iden-
iﬁed by the computerized literature search. In the ﬁnal step, 5
ournals with the highest impact factor in the ﬁeld of psychiatry
ere additionally searched for potential articles of interests. There
as no language restriction, although all the included papers were
n English.
.1.2. Selection criteria
Studies were included if they met  the following criteria: (a)
ere reported in an original paper in a peer-reviewed jour-
al, (b) had involved subjects with DSM-IV, DSM-III-R or ICD-10
chizophrenia (c) had employed volumetric MRI  in a longitudi-
al design (baseline/follow-up study); (d) had evaluated relative
ontributions of at least one potential moderator (illness duration,
ntipsychotic treatment, illness severity) of brain volume change.
he latter was deﬁned as cumulative exposure of antipsychotics
uring the inter-scan interval and computed as chlorpromazine
quivalents (Ho et al., 2011) (see S1 paragraph 9). When stan-
ardized diagnosis of psychotic subjects was not clearly deﬁned,
he study was excluded. Voxel Based Morphometry (VBM), Corti-
al Pattern Matching, Diffusion Tensor Imaging, Tractography or
ther techniques that do not report absolute brain volumes were
ot included. When there were two or more studies from the same
enter we contacted the authors to clarify whether there was  over-
ap in the respective samples (if several articles dealt with the same
opulation, we selected the article with the largest sample). When
tudies did not report data to compute the chlorpromazine equiva-
ents or other signiﬁcant data we carefully contacted the respective
uthors to collect the individual scores and avoid biases in the lit-
rature search.
.1.3. Recorded variables
The variables recorded from each article included in the meta-
nalysis were: sample size, year of publication, gender (proportion
f females), mean age of participants, duration of follow-up, dura-
ion of illness, type of antipsychotic treatment, daily dose of
ntipsychotic at the follow-up MRI  (chlorpromazine equivalents),
revious exposure to antipsychotics, brain volumes (see below),
everity of psychotic symptoms (see below). To achieve a high
tandard of reporting we have adopted ‘Preferred Reporting Items
or Systematic Reviews and Meta-Analyses’ (PRISMA) guidelines
Moher et al., 2009) (see Fig. 1).
.1.4. Extraction and standardization of psychometric rating
cales
There are several scales to measure psychotic symptoms used in
tudies with schizophrenia patients. Most commonly the Positive
nd Negative Symptom Scale (PANSS), and the Brief Psychiatric Rat-
ng Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS),
nd Scale for Assessment of Negative Symptoms (SANS) have been
sed. There is high correlation among both positive and negative
cale totals across these tools (Leucht et al., 2006) with good inter-
ater and test-retest reliability (Lyne et al., 2012). We  extracted
otal PANSS, BPRS and SAPS + SANS scores from included studies.avioral Reviews 37 (2013) 1680–1691
Each item of the SAPS and SANS is rated on a six point scale (0–5)
and BPRS and PANSS on a seven point scale (1–7). Extracted total
scores were transformed to a total score with a baseline of zero,
in line with previous studies (Sherwood et al., 2006)(see S1). To
investigate the baseline psychotic symptoms in included studies
we calculated mean per-item score by dividing the total score by 30
in PANSS, by 18 in BPRS and by 50 in SAPS + SANS. All included stud-
ies reported improvement on psychometric score during follow-up
and we  calculated it as percentage of baseline per-item score
(Agid et al., 2003b). The details of clinical variables used in the
meta-analysis are described in the supplementary material S1,
paragraph 8.
2.1.5. Quality assessment
The quality of the studies was  assessed using an item-checklist
constructed speciﬁcally for the review and similar to the previously
published quality assessment (Paulson and Bazemore, 2010). The
recorded variables were assessed in terms of precision, directness
and consistency of the data. The categories scored in the quality
assessment are listed in the table S2 with the range min 0 and max
2 points. The code of the range was  developed a priori and modiﬁed
after the ﬁrst run of quality assessment (see S1). The disagreements
were discussed between the authors and the consensus was  put in
the table. Quality assessment was conducted in the following cate-
gories: (1) study design – random blind, open or case–control, the
role of the funding and sample size; (2) demographic and clinical
characteristics – clearly reported inclusion and exclusion criteria,
substance abuse, included control group, gender, race, IQ, duration
of the illness and previous antipsychotic medication; (3) results
– reported drop-out rates, psychopathological ratings, statistical
thresholds, ROI reliability. The included studies were rated accord-
ing to the sum of the points and characterized as high quality (above
80% of the maximal sum of points), moderate-high (60–79%), mod-
erate (40–59%), moderate-low (20–39%), and low quality studies
(below 19%)(see more details in Tables S2 and S3).
2.2. Statistical analysis
Data were entered into an electronic database and analyzed
with a quantitative meta-analytical approach using Comprehensive
Meta-Analysis (CMA) Software version 2 (Biostat, Inc., Englewood,
NJ, USA). CMA  software employs the same computational algo-
rithms used by the Cochrane collaborators to weight studies by
the inverse variance method (Borenstein et al., 2005). The primary
effect size measure was the difference in brain volumes between
patients and controls at baseline and at the end of follow-up (see
S1). Meta-analyses were conducted when at least three studies
reported the volume of a common brain region. We  were thus able
to analyze the following regions: gray matter volume (GMV), white
matter volume (WMV), cerebrospinal ﬂuid (CSF) and whole brain
volume (WBV) as a sum of gray matter plus white matter volume
(Courchesne et al., 2000). Most included studies reported volumet-
ric data (WBV and/or GMV  and/or WMV)  including the volume of
cerebellum. For studies where global volumes did not include cere-
bellar volume, we either present the data received directly from the
author (van Haren et al., 2008) or marked them if the authors did
not respond (Sporn et al., 2003; Takahashi et al., 2009; Boonstra
et al., 2011; Ho et al., 2011) (Table 1) and adjusted our analysis
accordingly (sensitivity analysis, see below). We also analyzed lat-
eral ventricle volumes (LV) and the caudate nuclei volumes (Cd),
deﬁned as the sum of the left and right nuclei caudate. After com-
pleting a meta-analysis of progressive brain changes in patients and
controls (at baseline and follow-up) we speciﬁcally tested the effect
of putative moderator factors: cumulative antipsychotic exposure,
duration of illness and illness severity.
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The effect size was estimated by calculating Hedges’ unbiased g.
or the cross-sectional analysis, negative values reﬂected less gray
atter volumes in the patients as compared to healthy controls.
or the longitudinal analysis, negative values reﬂected brain vol-
mes reductions at follow-up as compared to baseline. To limit
isk of false positive (type I) errors arising from multiple com-
arisons we adjusted p < 0.05 by dividing  with the number of
eta-analyses conducted. The Q statistic was used to determine
etween-group differences. To determine whether categorical fac-
ors (i.e. substance abuse) modiﬁed the progressive brain changes,
ubgroup analyses were performed (Paulson and Bazemore, 2010).
he inﬂuence of continuous moderator variables (antipsychotic
xposure, duration of illness and illness severity and study dura-
ion) was tested using meta-regression analyses. Meta-regressions
ﬁxed effect models) were performed when at least seven inde-
endent studies were available for the outcome of interest. The
lope of meta-regression (ˇ-coefﬁcient: direct (+) or inverse (−))
f the regression line indicates the strength of a relationship
etween moderator and outcome. The confounding effect of poten-
ial outliers on the meta-regression was controlled with the Cook’s
istance test (Cook and Weisberg, 1982).
Heterogeneity among study point estimates was assessed with
he Q statistic (Paulson and Bazemore, 2010) with magnitude of
eterogeneity being evaluated with the I2 index (Lipsey and Wilson,
000). For homogeneous data, we calculated the global effect size,
sing a ﬁxed effect model. In the absence of signiﬁcant heterogene-
ty, the use of a ﬁxed effect model is legitimate and may  provide
reater statistical power than the random effect model (Szoke
t al., 2008). For heterogeneous data we employed random effects with the reason why they were excluded are listed in the supplementary Table 3.
V, lateral ventricles; VBM, voxel-based morphometry; WBV, whole brain volume;
models which are more conservative than ﬁxed-effect models, and
appear to better address heterogeneity between studies and study
populations, allowing for greater ﬂexibility in parsing effect size
variability (Cooper et al., 2009). Studies with negative results are
less likely to be published than studies with statistically signiﬁcant
results. The possibility of small publication biases in the present
study was  examined by visually inspecting funnel plots and apply-
ing the regression intercept of Egger et al. (1997). In this way we
assessed whether there was a tendency for selective publication of
studies based on the nature and direction of their results. In addi-
tion, we  used the fail-safe procedure (Orwin, 1983), to generate
a number of unpublished studies that would be needed to move
estimates to a non signiﬁcant threshold. In case of publication bias
we adopted the ‘trim and ﬁll’ method, which aims both to identify
and correct for funnel plot asymmetry arising from publication bias
(Duval and Tweedie, 2000). To assess the robustness of the results,
we performed sensitivity analyses by sequentially removing each
study and rerunning the analysis. We  also conducted a separate
analysis excluding studies with quality ratings in the lowest third
to determine if potential methodological weaknesses inﬂuenced
meta-analytic estimates. Finally we conducted a sensitivity analysis
excluding the studies that had not included cerebellar volumes.
3. Results3.1. Database
The initial literature search uncovered 116 potential studies.
Out of the 65 full-text assessed studies, 35 did not meet inclusion
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Table 1
Longitudinal magnetic resonance imaging studies of schizophrenia subjects and antipsychotic exposure included in the meta-analysis.
Author & year Brain volumetric data
used in analysis
Follow-up duration Type of
antipsychotic
Previous antipsychotic
medication
Substance
abuse
Schizophrenia patients Healthy controls
Weeks
means
SD Y (%) Y/N n Age years SD % F n Age years SD % F
Arango 2012 (Arango et al.,
2012)
WBV, GMV, WMV,  CSF 104.8 12.00 MIX  Y (96) N 25 15.50 2.00 28.00 94 15.30 1.50 67.00
Boonstra  2011 (Boonstra
et al., 2011)
WBV, GMV*, WMV*,
LV, NC
57.27 8.55 ATYP Y (100) Y 8 FE AF 27.97 8.24 25.00 20 27.97 5.63 33.30
54.00  0.84 ATYP Y (100) Y 8 FE 29.56 5.72 25.00
Chakos  1994 (Chakos et al.,
1994)
LV, NC 72.00 . TYP Y (27.5) N 29 25.20 6.30 41.30 10 30.50 4.90 20.00
Crespo-Facorro 2008
(Crespo-Facorro et al.,
2008)
WBV, GMV, WMV,  LV,
NC
54.60 4.60 TYP NA Y 18 Hal 29.76 7.88 38.90 38 Matched . 31.60
55.30 4.20 ATYP  NA Y 18 Olan 28.00 5.09 27.80 . .  .
53.70  3.50 ATYP NA Y 16 Risp 24.99 5.96 18.70 . .  .
DeLisi  2004 (DeLisi et al.,
2004)
LV 520.00 . MIX  Y NA 26 26.80 7.08 34.60 20 25.50 . 40.00
Frazier  1996 (Frazier et al.,
1996)
LV, NC 104.00 . Clo/MIX Y NA 8 15.10 2.30 13.00 8 15.40 3.10 12.50
Garver  2005 (Garver et al.,
2005)
WMV,  CSF 4.00 . TYP Y N 6 32.20 14.80 33.00 7 29.00 9.00 28.60
4.00  . ATYP Y N 13 31.60 10.20 31.00 . .  . .
Gur  1998 (Gur et al., 1998) WBV  119.20 48.80 MIX  N (100) NA 20 FE 29.20 8.00 42.50 17 31.90 8.90 23.50
WBV  119.20 48.80 MIX  Y (100) NA 20 Ch 29.20 8.00 42.50 . .  . .
Heitmiller  2004 (Heitmiller
et  al., 2004)
NC 120.80 . ATYP N NA 14 26.30 6.80 50.00 14 26.70 11.30 50.00
Ho  2011 (Ho et al., 2011) GMV* 374.40 202.80 MIX  Y (86) Y 211 26.30 7.60 28.00 . .  . .
Ho  2003 (Ho et al., 2003) WBV  171.00 83.20 MIX  Y (55) NA 73 24.50 4.67 27.00 23 26.90 1.60 34.80
James  2004 (James et al.,
2004)
WBV  125.84 82.68 Cloz/ATYP Y (70) NA 9 M 17.70 1.70 . 9 M 15.70 2.00 .
88.92 27.04 Cloz/ATYP Y (38) .  7 F 15.30 1.50 . 7 F 16.40 2.10 .
Keshavan  1994 (Keshavan
et al., 1994)
NC 43.57 TYP N NA 11 . . . . .  . .
Lang  2004 (Lang et al.,
2004)
NC 56.00 17.10 ATYP Y (100) N 10 35.30 8.80 30.00 23 23.30 7.40 47.80
52.10  6.90 ATYP Y (100) N 14 23.70 3.30 28.60 . .  . .
42.20  12.10 ATYP Y (100) N 13 25.60 8.20 23.10 . .  . .
Lieberman  2005
(Lieberman et al., 2005)
WBV, GMV, LV 52.00 . TYP Y (67.1) N 79 24.11 4.64 10.00 62 25.53 4.13 35.50
52.00  . ATYP Y (76.8) N 82 23.60 4.64 21.00
Massana  2005 (Massana
et al., 2005)
NC 9.00 . ATYP N NA 11 23.00 4.00 27.00 . .  . .
McClure  2008 (McClure
et al., 2008)
NC 12.00 . ATYP/Cloz Y N 10 36.70 7.70 10.00 . .  . .
Molina  2005 (Molina et al.,
2005)
WBV, GMV, WMV  102.40 39.60 ATYP N (100) N 49 25.60 4.00 31.00 11 28.40 6.20 54.50
114.80  47.20 Clo Y N 29Ch 31.00 5.90
Nakamura 2007
(Nakamura et al., 2007)
WMV,  LV 72.40 46.40 ATYP Y N 17 FE 24.70 7.00 17.70 26 23.60 4.10 15.40
Puri  2001 (Puri et al., 2001) LV 30.90 6.20 MIX  Y N 24 28.47 8.45 . 12 27.92 6.14 .
Reig  2009 (Reig et al., 2009) GMV, WMV,  CSF 104.00 . Cloz/ATYP Y N 21 15.70 1.70 23.80 34 15.20 1.40 38.20
Saijo  2001 (Saijo et al.,
2001)
LV 520.00 . NA NA N 18 37.50 8.90 50.00 12 37.10 4.20 41.70
Scheepers  2001 (Scheepers
et al., 2001)
WBV, NC 24.00 . CLOZ Y (100) N 29 35.23 10.34 30.80 . .  . .
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criteria and were excluded. The ﬁnal database comprised 30 orig-
inal independent studies published between 1994 and 2012. The
overall sample was  of 1046 schizophrenia patients and 780 controls
for a median duration of follow-up of 72.4 weeks (range 4–520).
The details of the literature search are described in the PRISMA
ﬂowchart, while the characteristics of the included and excluded
studies are detailed in Table 1 and supplementary material S4
respectively.
3.2. Baseline differences in brain volumes
After correcting for multiple comparisons, we found signiﬁcant
baseline volumetric differences in the WBV, with patients show-
ing reduced volumes as compared to controls (p = 0.002, Table 2).
Conversely, patients showed enlarged LV volumes as compared
to controls (p < 0.001). There were trend-level differences in the
reduced GMV, which however did not survive correction for mul-
tiple comparisons. Increased cerebrospinal ﬂuid was  observed in
patients but this occurred in the presence of publication bias (see
below). There were no signiﬁcant baseline differences in WMV  or
caudate nucleus (Cd) volume.
3.3. Longitudinal difference in brain volumes
When WBV  at the end of the follow-up was  compared with
the baseline values, there was  an overall decrease, which how-
ever was not statistically signiﬁcant for both the patient (p = 0.339)
and control (p = 0.333) groups (between groups difference p = 0.923,
Table 3). Similarly, there were non-signiﬁcant volume decreases in
the Cd for both patients (p = 0.913) and controls (p = 0.160) groups
(between groups difference p = 0.318).
Signiﬁcant longitudinal volumetric changes were observed in
the GMV  and LV. The ﬁrst showed signiﬁcant volumetric decreases
in patients (p = 0.002) but not in controls (p = 0.094). The differences
in the patient group survived correction for multiple comparisons.
There was  a signiﬁcant between group differences in longitudinal
GMV  changes (Q = 5.974, p = 0.044; Table 3). There were signiﬁcant
LV increases in the patient (p = 0.002) but not in the control group
(p = 0.102). The differences in the patient group survived correction
for multiple comparisons and a signiﬁcant between-group differ-
ence was detected (Q = 9.566, p = 0.029, Table 3).
WMV  and CSF showed non-signiﬁcant increases at follow-up
as compared to baseline across both patients (WMV  p = 0.998, CSF
p = 0.970) and control (WMV  p = 0.108, CSF p = 0.391) groups (WMV
between groups differences p = 0.262, CSF between groups differ-
ences p = 0.185).
3.4. Effects of moderators
The details of antipsychotic treatment, symptoms severity, and
duration of illness are given in supplementary Tables S5 and S6).
Meta regression analyses for the selected moderators (cumulative
exposure to antipsychotic medication during follow-up time, psy-
chotic symptoms change over follow-up and duration of illness)
were tested for both GMV  and LV changes in the patient group. Lon-
gitudinal GMV  decreases in patients were associated with higher
cumulative exposure to antipsychotic over time (n of studies = 8
(Sporn et al., 2003; Lieberman et al., 2005; Molina et al., 2005;
Crespo-Facorro et al., 2008; van Haren et al., 2008; Boonstra et al.,
2011; Ho et al., 2011; Arango et al., 2012), sample = 629 schizophre-
nia subjects,  ˇ = −0.013, CI 95% from −0.033 to −0.001, Q = 8.598,
p = 0.048, Fig. 2a) but not with psychotic symptoms change (n of
studies = 7 (Sporn et al., 2003; Lieberman et al., 2005; Molina et al.,
2005; Crespo-Facorro et al., 2008; van Haren et al., 2008; Reig
et al., 2009; Arango et al., 2012), sample = 418 schizophrenia sub-
jects, p > 0.05, Fig. 2b) or DOI (n of studies = 9 (Sporn et al., 2003;
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Table  2
Meta-analyses of baseline volumetric differences between schizophrenia patients and healthy controls. Negative values of Hedge’s g indicate reduced volume in patients vs.
controls.
Brain region N SCZ C Hedge’s g Z score p Test for Heterogeneity FSN ERT Trimm and Fill
Mean CI95% Q I2 p Mean CI95%
WBV  11 581 429 −0.252 −0.414 −0.091 −3.063 0.002* 13.561 26.26 0.194 27 0.411 −0.252 −0.414 −0.091
GMV  8 399 382 −0.192 −0.343 −0.041 −2.493 0.013 3.635 3.7 0.821 18 0.111 −0.192 −0.343 −0.041
WMV  6 199 261 −0.012 −0.294 0.269 −0.087 0.931 8.717 42.64 0.121 0 0.393 −0.012 −0.294 0.269
CSF  3 60 98 0.451 0.088 0.813 1.434 0.045 2.173 7.90 0.337 3 0.069 0.325 −0.037 0.686
LV  11 549 347 0.309 0.144 0.467 4.046 <0.001* 12.084 17.25 0.279 44 0.139 0.309 0.144 0.467
Cd  9 192 171 0.116 −0.107 0.339 1.020 0.308 8.589 6.85 0.378 0 0.592 0.116 −0.107 0.339
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FBV, whole brain volume; GMV, grey matter volume; WMV,  white matter volum
tudies  included in each meta-analysis; SCZ, number of patients with schizophrenia
ail  Safe Number; ERT, Egger’s Regression Test.
ieberman et al., 2005; Molina et al., 2005; Crespo-Facorro et al.,
008; van Haren et al., 2008; Reig et al., 2009; Boonstra et al., 2011;
o et al., 2011; Arango et al., 2012), sample = 645 schizophrenia
ubjects, p > 0.05, Fig. 2c). Longitudinal LV changes in patients were
ot associated with cumulative exposure to antipsychotics (n of
tudies = 10 (Chakos et al., 1994; Frazier et al., 1996; Puri et al., 2001;
aijo et al., 2001; Ho et al., 2003; Sporn et al., 2003; Lieberman et al.,
005; Nakamura et al., 2007; van Haren et al., 2008; Boonstra et al.,
011), sample = 533 schizophrenia subjects, p < 0.05) or DOI (n of
tudies = 11 (Frazier et al., 1996; Puri et al., 2001; Saijo et al., 2001;
o et al., 2003; Sporn et al., 2003; DeLisi et al., 2004; Lieberman
t al., 2005; Whitworth et al., 2005; Nakamura et al., 2007; van
aren et al., 2008; Boonstra et al., 2011), sample = 542 schizophre-
ia patients, p > 0.05, Fig. 3). Because of missing data (n of studies
7) it was not possible to conduct a meta-regression between
V changes and psychotic symptoms changes in patients. There
as no signiﬁcant confounding effect for study duration on the
ongitudinal GMV  changes (  ˇ = −0.0006, CI 95% from −0.001 to
.001, Z = −1.772, p = 0.096). Although studies with a longer dura-
ion tended to detect larger LV enlargements as compared to studies
ith a short follow-up, this effect was non signiﬁcant (  ˇ = 0.001, CI
5% from −0.001 to 0.002, Z = 1.413, p = 0.158).
.5. Publication bias, heterogeneity, sensitivity analysis
As also shown in Table 2, the fail-safe number in the baseline
nalysis surpassed the number of actual studies by a factor 2.25
GMV) up to a factor 4 (LV). Conversely, both the fail-safe number
nd the Egger’s regression test indicated publication bias for CSF.
igniﬁcance of Hedge’s g did not survive after adjustment by the
able 3
eta-analyses of longitudinal volumetric differences between schizophrenia patients and
s  baseline.
Brain region N Group Hedge’s g Z score p 
Mean CI95% 
WBV  12 CTRL −0.069 −0.208 0.070 −0.969 0.3
SCZ  −0.060 −0.183 0.063 −0.956 0.3
GMV  9 CTRL −0.143 −0.293 0.008 −1.555 0.0
SCZ  −0.249 −0.399 −0.093 −3.154 0.0
WMV  8 CTRL 0.148 −0.032 0.328 1.608 0.1
SCZ  0.001 −0.184 0.184 0.002 0.9
CSF  3 CTRL 0.199 −0.256 0.654 0.858 0.3
SCZ  0.007 −0.339 0.352 0.037 0.9
LV  12 CTRL 0.129 −0.025 0.283 1.637 0.1
SCZ  0.207 0.075 0.339 3.067 0.0
Cd  13 CTRL −0.149 −0.357 0.059 −1.405 0.1
SCZ  −0.010 −0.183 0.164 −0.109 0.9
BV, whole brain volume; GMV, grey matter volume; WMV,  white matter volume; CS
tudies  included in each meta-analysis; SCZ, number of patients with schizophrenia; C, n
ail  Safe Number; ERT, Egger’s Regression Test.F, cerebrospinal ﬂuid; LV, lateral ventricules; Cd, Caudate nucleus; N = number of
umber of controls; *Surviving correction for multiple comparisons (p = 0.008); FSN,
Trim and Fill method. Fail-safe numbers were generally larger in the
longitudinal analysis. Egger’s regression test did not indicate publi-
cation bias here and signiﬁcance of effect sizes did not change after
adjustment by the Trim and Fill method. Heterogeneity was low
and non-signiﬁcant in the cross-sectional analysis. The presence of
statistically signiﬁcant heterogeneity of low magnitude in the lon-
gitudinal analysis accounted for the exploratory investigations of
potential moderator factors. Quality analysis showed that most of
the included studies were of high or moderate quality (13.3% high
and 73.3% moderate scores). Removing studies with quality ratings
in the lowest third did not affect the point estimates by more than
8.5%. The results of the sensitivity analysis excluding studies that
did not include cerebellar volumes, did not affect the overall base-
line meta-analytical estimates more than 7% (GMV: 7%, WMV  4%,
WBV  6%).
4. Discussion
The present meta-analysis investigated longitudinal gray matter
changes in schizophrenia addressing the impact of illness dura-
tion, severity of psychotic symptoms and antipsychotic treatment.
Thirty longitudinal MRI  studies were included with ﬁnal database of
1046 schizophrenia patients and 780 controls. At the baseline cross-
sectional analysis, the patients showed signiﬁcant WBV  reductions
and enlarged LV volumes as compared to controls but no abnor-
malities in GMV, WMV,  CSF and Cd. Longitudinally, there were
progressive GMV  decreases and LV enlargements in the schizophre-
nia group while no signiﬁcant changes were observed in control
group. The higher the cumulative exposure to antipsychotic treat-
ment the greater the GMV  decreases in the patient group over
 healthy controls. Negative values of Hedge’s g indicate reduced volume at follow-up
Between
groups effect
FSN ERT Trim and Fill
Q p Mean CI95%
33 0.009 0.923 0 0.662 −0.069 −0.208 0.070
39 −0.060 −0.183 0.063
94 5.974 0.044 21 0.742 −0.143 −0.293 0.008
02* −0.249 −0.399 −0.093
08 1.259 0.262 0 0.341 0.148 −0.032 0.328
98 0.001 −0.184 0.184
91 1.759 0.185 0 0.351 0.199 −0.256 0.654
70 0.007 −0.339 0.352
02 9.566 0.029 34 0.178 0.129 −0.025 0.283
02* 0.207 0.075 0.339
60 0.996 0.318 0 0.409 −0.149 −0.357 0.059
13 −0.010 −0.183 0.164
F, cerebrospinal ﬂuid; LV, lateral ventricules; Cd, Caudate nucleus; N = number of
umber of controls; *Surviving correction for multiple comparisons (p = 0.008); FSN,
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Fig. 2. Meta-regression analysis: (a) progressive GMV  changes and cumulative exposure to antipsychotics (  ˇ = −0.013, CI 95% from −0.033 to −0.001, Q = 8.598, p = 0.048);
(b)  progressive GMV  changes and duration of illness (DOI,  ˇ = 0.001, CI 95% from −0.001 to 0.001, p = 0.653); (c) progressive GMV  changes and psychotic symptoms change
over  follow-up time (  ˇ = 0.002, CI 95% from −0.011 to 0.016, p = 0.732). The size of the circle reﬂects the sample size of the study. Negative vaules on the y axis indicate
brain  volume reductions at follow-up as compared to baseline. Cumulative exposure to antipsychotics unit was deﬁned in Chlorpromazine Equivalent per day (CPZ-EQ/d)
multiplied by the duration of the medication treatment in days (for details see Supplementary material study protocol para. 9). Change in psychotic symptom unit: percentage
of  baseline per item score (positive values indicate improvement of symptoms at follow-up as compared to baseline; for details see supplementary materials section
8).
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Gig. 3. Meta-regression analysis showing no signiﬁcant (p > 0.05) correlations betwe
atients. The size of the circle reﬂects the sample size of the study. Positive values o
ollow-up time, while no signiﬁcant effects were observed for ill-
ess duration or severity of symptoms.
Our systematic literature search uncovered a large database
f 30 longitudinal MRI  studies with antipsychotic administration.
he large sample size combined with the absence of signiﬁcant
ublication biases (except for CSF), low heterogeneity between
tudies, strict quality control and careful sensitivity analysis yielded
 robust meta-analytical approach. We  ﬁrst conducted a cross-
ectional analysis to address putative brain changes prior the
nitiation of the longitudinal MRI  studies. Patients compared to
ontrols had reduced WBV  and enlarged LV with trend-level
eductions in GMV, which did not survive multiple compar-
sons. A recent meta-analysis has addressed the cross-sectional
rain volume changes in medicated schizophrenia patients; small
o medium meta-analytical differences were conﬁrmed in WBV
effect size = −0.17), GMV  (−0.43) and LV (0.45) (Haijma et al.,
012). In line with these ﬁndings, our cross-sectional analysis
etected similar small to medium magnitude in the observed effect
izes: WBV  (−0.25), GMV  (−0.19), LV (0.31). However, these ﬁnd-
ngs are based on cross-sectional designs and thus it is not possible
o establish whether these alterations are secondary to previous
ntipsychotic treatments, illness duration or illness severity or a
ixture of these or other confounding factors. Furthermore, as
oderate atrophy of gray matter structures has been observed dur-
ng normal aging (Long et al., 2012) it is not clear whether similar
ynamic alterations occur in healthy individuals.
To address these caveats we have conducted a meta-analytical
omparison of WMV,  GMV, CSF, WBV, LV, and Cd volumes from
ongitudinal studies in patients with schizophrenia vs. controls.
e found progressive GMV  reductions and LV enlargements
n schizophrenia patients but not in healthy controls. Previous
vidence has indicated that the annualized percentage volume
hanges in schizophrenia were −0.59% for GMV, and +0.36% for
V (Olabi et al., 2011). The overall effect sizes for our longitudi-
al LV increases over follow-up time were small to medium: 0.21
n patients and 0.13 in controls. LV increases (approximately 130%
he size of normal controls (Wright et al., 2000)) are the earliest
identiﬁed by CT imaging in 1976) (Johnstone et al., 1976) and the
ost consistent volumetric abnormalities reported in schizophre-
ia (Kempton et al., 2010), in up to 66% of available studies (Sayo
t al., 2012). We  found no modulating effect of antipsychotic treat-
ent or illness duration on progressive LV increases. Previous
orks suggested that LV enlargement is globally interrelated with
MV  diminution (Horga et al., 2011). In line with this hypothesisogressive LV volume changes and duration of illness (DOI) within the schizophrenia
 y axis reﬂect brain volume increases at follow-up as compared to baseline.
we also uncovered longitudinal GMV  reductions. Overall the effect
size for the longitudinal GMV  decreases over follow-up time was
again small to medium: −0.25 and in the patient and −0.14 in the
control group. Interestingly, the magnitude of progressive GMV
decreases was  very close to that observed for LV increases, in line
with the hypothesis that progressive cortical shrinkage over time
might largely explain LV increases. To test that there was a patho-
logical difference in the longitudinal progression of brain changes
we compared the magnitude of changes between the patient and
control group. The between-groups difference in GMV  and LV was
statistically signiﬁcant, indicating that the schizophrenia patients,
compared to matched healthy controls, showed pathological pro-
gressive GMV  decreases and LV increases. However, it is important
to note that the lack of signiﬁcant progressive changes in controls
may  be a matter of power and variability in included groups. Sim-
ilarly, our group-level analysis cannot exclude that the observed
pathological changes can occur only in a subset of schizophrenia
patients (Andreasen et al., 2011).
Given the longitudinal design we  then tested the potential effect
of the above confounders in the schizophrenia group: antipsychotic
cumulative dose during the MRI  study, overall duration of illness,
and changes of illness severity i.e. psychotic symptoms during the
MRI  study. The core ﬁnding of the present meta-analysis is that
longitudinal GMV  decreases in schizophrenia patients were asso-
ciated with higher cumulative exposure to antipsychotic over time,
while no effects were observed for duration of illness and severity
of symptoms. To our best knowledge this is the ﬁrst time there
is meta-analytical longitudinal evidence for a signiﬁcant correla-
tion of antipsychotic treatment and progressive GMV  changes in a
large sample of schizophrenia subjects (n = 629). Our longitudinal
result reinforces the previous cross-sectional evidence indicating
that GMV  loss was  more pronounced in patients using a higher
dose of antipsychotic medication (atypical but not typical) at time
of scanning (Haijma et al., 2012). The merit of our investigation is
that rather than using the current dose of antipsychotic medication
we employed the cumulative exposure to antipsychotic treatment
during follow up, accounting for the exact duration of longitu-
dinal exposure. Our result of structural changes associated with
antipsychotic treatment is in line with functional ﬁndings indi-
cating that antipsychotics inﬂuence neural activity in psychosis,
even in the short-term period (Fusar-Poli et al., 2007; Lui et al.,
2010). The putative mechanism of action of antipsychotics on
GMV  is unknown and can only be inferred in vivo from animal
studies. Chronic exposure of macaque monkeys to haloperidol or
iobeh
o
i
t
d
w
i
h
c
d
n
G
t
r
w
d
e
n
p
c
v
M
i
t
p
w
ﬁ
j
a
c
2
i
e
r
t
c
i
s
2
o
c
u
s
(
u
v
t
t
b
n
m
u
c
a
d
i
p
i
w
u
e
T
b
a
a
d
tP. Fusar-Poli et al. / Neuroscience and B
lanzapine was associated with a 10–18% lower glial cell number
n the gray matter (Konopaske et al., 2008). A recent investigation
ested the hypothesis that chronic treatment with antipsychotic
rugs is associated with a decrease in brain cortical volume,
hereas treatment with mood stabilizers is associated with an
ncrease in cortical brain volume (Vernon et al., 2012). Chronic
aloperidol treatment induced decreases cortical GMV; in contrast,
hronic lithium treatment induced increases in GMV. Following
rug withdrawal, haloperidol-induced changes in brain volumes
ormalized (Vernon et al., 2012). However, some studies showed
MV  continues to decline in the same patients following discon-
inuation of antipsychotics (Boonstra et al., 2011). Such a ﬁnding
einforces the hypothesis that schizophrenia may  be associated
ith progressive morphologic changes to which antipsychotic
rugs may  contribute but are not the sole cause (Andreasen
t al., 2011). However, the present meta-analysis contradicts expla-
ations that progressive brain losses are simply a correlate of
oor clinical outcome, for which antipsychotic medication is only
onsidered any epiphenomenon. In fact, in a recent multimodal
oxel-based meta-analysis combining functional and structural
RI  studies we showed that anterior cingulate and insula were
nﬂuenced by exposure to antipsychotics: GMV  abnormalities in
hese regions were signiﬁcantly more severe in medicated as com-
ared to drug naïve patients (Radua et al., 2012). As GMV  alterations
ere already observed in meta-analyses of antipsychotic-naïve
rst-episode subjects (Fusar-Poli et al., 2012c), as well as in sub-
ects at high clinical risk for psychosis (Fusar-Poli et al., 2011),
ntipsychotics may  target regions of key pathology in early psy-
hosis, without necessarily causing these alterations (Radua et al.,
012). Consequently, we speculate that progressive brain changes
n schizophrenia may  be related to a combination of antipsychotic
ffects as well as illness progression-reﬂected in concurrent GMV
eduction and LV enlargements (Horga et al., 2011). There are limi-
ations to consider in the present study. First, meta-analyses usually
arry on the methodological limitations of the individual studies
ncluded in their database. Older studies may  be characterized by
mall sample sizes and overall poor quality control (Shepherd et al.,
012). When reporting whole brain volume some studies did and
thers did not included cerebellar volume in their data. We have
ontrolled for this issue in our analysis. Importantly, cerebellar vol-
me  tends to be conserved over disease progression showing no
igniﬁcant differences over time (Andreasen et al., 2011) or are
not signiﬁcantly) mirroring the pattern of the cerebral GM vol-
me  (van Haren et al., 2008). We  thus conclude that cerebellar
olume, remaining unchanged over time, is not contributing to
he longitudinal brain changes we detected. It is also important
o note that we could not test the hypothesis that the changes in
rain volume are nonlinear (the biggest at the beginning of the ill-
ess), as indicated by recent studies (Andreasen et al., 2011). Other
ethodological issues such as potential role of different scanners
sed, their upgrades, and software used in calculating brain volume
hange (de Bresser et al., 2011) could have inﬂuenced the results
s well. However, to address this potential problem we have con-
ucted a careful quality assessment and used the sum of scores
n our analysis, uncovering no signiﬁcant changes on the principal
oint estimates. Nonetheless, the pattern of volumetric changes
n the brain vary with age: in young adults gray matter declines
hilst white matter increases, while in older adults these meas-
res both decline with age. In addition aging has a differential
ffect on regional brain in males and females (Good et al., 2001).
hese sources of variability were not integrated in our analysis,
ut should be considered when interpreting our results. Addition-
lly, there are potential alternative factors that may  account for the
ssociation between brain volume and medication and which were
ifﬁcult to control in our meta-analysis. In particular, our approach
o quantify moderator variables, (e.g. medication taken during theavioral Reviews 37 (2013) 1680–1691 1689
follow-up period calculated in CPZ equivalents, or difﬁculty stan-
dardizing symptom measures across different scales) were based
on assumptions that could differ from the ideal situation where
raw individual patient data would be available to analyze. Another
limitation underlying volumetric MRI  meta-analyses can be that
the individual studies usually rely on ROI approaches, which are
manually traced. The manual tracing of ROIs, as compared to
automated methods such as VBM, can introduce signiﬁcant het-
erogeneity in the anatomical deﬁnition of brain areas introducing
biases in signiﬁcance of the results reported. In general, ROI anal-
yses can also be affected by publication biases: researchers could
perform several exploratory analyses but report only those which
yielded signiﬁcant results (Ioannidis, 2011; Radua and Mataix-Cols,
2012). Additionally, because of limited data available, we  were
unable to test all our research hypotheses. In particular we were
unable to test whether LV changes were longitudinally associ-
ated with psychopathological i.e. PANSS changes in schizophrenia
patients. Furthermore, we  were unable to test the correlation
between antipsychotic treatment and DOI and consequently assess
the “independent” effects of antipsychotic treatment on brain vol-
ume  changes. Finally, it is important to note that association is
not causation and thus our ﬁndings of signiﬁcant GMV  decreases
being correlated with cumulative exposure to antipsychotic treat-
ments should be interpreted cautiously. In particular, multifactorial
association implicating several alternative causal factors could
potentially underlie our core ﬁndings. In other words, antipsychotic
treatment may  not be the only factor associated to longitudinal
GMV  decreases in schizophrenia. This is supported by progressive
brain changes are already present before the onset and may in par-
ticular occur during transition of psychosis in antipsychotic-naïve
subjects (Pantelis et al., 2003; Borgwardt et al., 2008; Mechelli et al.,
2011; Borgwardt et al., 2012). Moreover, as we did not assess effects
of conventional vs. atypical antipsychotics we  cannot comment
on potential differential and modulating effects on progression
(Weinberger and McClure, 2002; Lieberman et al., 2005; Hulshoff
Pol and Kahn, 2008). Other potential confounders factors (Collin
et al., 2012) such as the genetic modulation of progressive brain
changes (Andreasen et al., 2012) or the role played by early cog-
nitive deﬁcits (Fusar-Poli et al., 2012b; Koutsouleris et al., 2012)
or substance abuse (Rais et al., 2008; Martin-Santos et al., 2010)
on gray matter changes should become subject of investigation by
future original studies.
5. Conclusions
Schizophrenia is characterized by progressive gray matter vol-
ume  decreases and lateral ventricular volume increases. Some of
these neuroanatomical alterations may  be correlated with antipsy-
chotic treatment.
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